Second-line 90yttrium-ibritumomab tiuxetan (Zevalin) in a patient with conjunctival mucosa-associated lymphoid tissue lymphoma refractory to rituximab

Patrick Oellers, Aaron Savar, Felipe Samaniego, Barbara Pro, Bita Esmaeli*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

Lymphoma of mucosa-associated lymphoid tissue (MALT) is the most common variety of lymphoma seen in the ocular adnexae. The authors present the case of a patient with MALT lymphoma refractory to treatment with rituximab. Subsequent treatment with 90Yttrium-Ibritumomab tiuxetan yielded a complete response.

Original languageEnglish (US)
Pages (from-to)e145-e146
JournalOphthalmic plastic and reconstructive surgery
Volume28
Issue number6
DOIs
StatePublished - Nov 1 2012

ASJC Scopus subject areas

  • Surgery
  • Ophthalmology

Fingerprint

Dive into the research topics of 'Second-line 90yttrium-ibritumomab tiuxetan (Zevalin) in a patient with conjunctival mucosa-associated lymphoid tissue lymphoma refractory to rituximab'. Together they form a unique fingerprint.

Cite this